Publications by authors named "G Bogani"
Article Synopsis
- This scoping review examines treatment options for genitourinary syndrome of menopause (GSM), a commonly overlooked condition caused by reduced estrogen levels during menopause, leading to various symptoms impacting women's quality of life.
- The review analyzed 451 articles and ultimately included 19 studies that highlight first-line treatments like lubricants and moisturizers, as well as hormonal therapies such as selective estrogen receptor modulators and DHEA for managing severe symptoms.
- It emphasizes the importance of tailored therapy and effective communication to help women make informed treatment choices while calling for more research into GSM therapies, especially concerning safety in women with cancer histories.
Growing evidence has demonstrated the role of mutations of tumor biomarkers in diagnosing and treating epithelial ovarian cancer. This review aims to analyze recent literature on the correlation between tumor biomarkers and chemotherapy in nonmucinous ovarian cancer, providing suggestions for personalized treatment approaches. An extensive literature search was conducted to identify relevant studies and trials.
View Article and Find Full Text PDFPurpose: To determine the prognostic impact of microscopic residual disease after neoadjuvant chemotherapy (NACT) in patients undergoing interval debulking surgery (IDS) for advanced epithelial ovarian cancer (AEOC).
Methods: Patients affected by FIGO stage IIIC-IV ovarian cancer undergoing IDS between October 2010 and April 2016 were selected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier analysis.
Ovarian cancer affects thousands of women every year and represents the female cancer with the highest mortality rate. Effectively, it is a severe disease that requires a multidisciplinary approach for optimal treatment. Surgery currently is the cornerstone of its treatment and numerous methods have been analyzed and developed to predict the possibility of obtaining a residual tumor of 0 (RT=0).
View Article and Find Full Text PDFBackground: Hysterectomy for endometrial hyperplasia and endometrial cancer in morbidly obese patients is challenging. Here, we reported data regarding three minimally invasive approaches.
Method: This is a multicenter retrospective study evaluating 30-day and 90-day surgery-related outcomes of morbidly obese patients (those with BMI > 40kg/m) undergoing robotic-assisted, laparoscopic, and vaginal hysterectomy.